Telix Pharmaceuticals (TLX) investor relations material

Key themes in PSMA therapy development

• Second-generation radioligand TLX597-Tx shows minimal off-target radiation to kidneys and salivary glands, with high tumor uptake, addressing toxicity concerns seen with first-generation agents in earlier-stage prostate cancer.

• Dose intensification and adaptive dosing are central to new trial designs, aiming to maximize tumor response while minimizing toxicity and improving patient quality of life.

• The portfolio approach includes both antibody-drug conjugates (TLX591-Tx) for late-stage disease and small molecules (TLX597-Tx) for earlier-stage, hormone-sensitive settings.

• Up-front dose intensification leverages PSMA upregulation after initial dose, increasing subsequent tumor uptake and maximizing cell kill.

• Adaptive dosing strategies, including treatment pauses based on imaging and PSA response, are being explored to avoid overtreatment and reduce long-term side effects.

Clinical trial insights and patient outcomes

• OPTIMAL-PSMA phase II trial evaluates intensified dosing regimens, with early data showing low toxicity and promising tumor targeting, even in heavily pretreated, high-volume metastatic castration-resistant prostate cancer patients.

• The trial includes broad eligibility, enrolling patients with high disease burden and prior exposure to multiple therapies, reflecting real-world populations.

• Early imaging and PSA data indicate deep tumor responses with intensified dosing, while maintaining low rates of hematological and organ toxicity.

• Patient case studies demonstrate substantial PSA reductions and lesion shrinkage, even in heavily pretreated individuals.

• OPTIMAL-PSMA trial has rapidly enrolled 90 of 120 patients at a single site, with most patients tolerating intensified regimens well and experiencing manageable side effects.

Dosimetry and safety profile

• TLX597-Tx demonstrates lower kidney and salivary gland radiation doses compared to PSMA-617 and PSMA-I&T, with higher tumor doses and prolonged retention.

• Dosimetry data confirm low radiation exposure to non-target tissues, supporting use in earlier-stage patients who require long-term quality of life preservation.

• TLX597-Tx demonstrates a favorable safety profile, with low rates of xerostomia, hematological toxicity, and minimal GI side effects compared to first-generation agents.

• Biodistribution supports more intensive regimens with reduced risk of overtreatment and toxicity, especially in healthier, earlier-stage patients.

• Early data show favorable safety, low renal and salivary gland uptake, and high tumor retention, supporting intensified dosing strategies.